Maury Raycroft
Stock Analyst at Jefferies
(0.85)
# 2,761
Out of 4,412 analysts
36
Total ratings
22.86%
Success rate
-14.61%
Average return
Main Sectors:
Top Industries:
23 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics | Maintains: Buy | $22 → $39 | $21.90 | +78.08% | 2 | Mar 22, 2024 | |
| CUE Cue Biopharma | Initiates: Buy | $6 | $1.42 | +322.54% | 1 | Mar 13, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Upgrades: Buy | $4 → $46 | $35.64 | +29.07% | 1 | Mar 6, 2024 | |
| MGX Metagenomi | Initiates: Buy | $23 | $8.10 | +183.95% | 1 | Mar 5, 2024 | |
| TPST Tempest Therapeutics | Initiates: Buy | $15 | $3.44 | +336.05% | 1 | Feb 8, 2024 | |
| BCRX BioCryst Pharmaceuticals | Upgrades: Buy | $11 | $4.27 | +157.61% | 3 | Aug 4, 2023 | |
| ALLK Allakos | Upgrades: Buy | $6 → $9 | $1.10 | +718.18% | 2 | May 12, 2023 | |
| CMPX Compass Therapeutics | Initiates: Buy | $8 | $1.46 | +447.95% | 1 | Jan 31, 2023 | |
| VERA Vera Therapeutics | Downgrades: Hold | $32 → $6 | $41.38 | -85.50% | 2 | Jan 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $92 → $75 | $23.13 | +224.25% | 2 | Nov 29, 2022 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $218 → $232 | $147.36 | +57.44% | 1 | Oct 3, 2022 | |
| RZLT Rezolute | Initiates: Buy | $11 | $2.61 | +321.46% | 1 | Sep 12, 2022 | |
| TYRA Tyra Biosciences | Upgrades: Buy | $31 → $27 | $16.45 | +64.13% | 3 | Mar 8, 2022 | |
| BYSI BeyondSpring | Downgrades: Hold | n/a | $2.22 | - | 2 | Dec 2, 2021 | |
| CELC Celcuity | Initiates: Buy | n/a | $16.05 | - | 1 | Sep 7, 2021 | |
| ASLN ASLAN Pharmaceuticals | Initiates: Buy | n/a | $0.46 | - | 1 | Jul 9, 2021 | |
| VALN Valneva SE | Initiates: Buy | n/a | $7.69 | - | 1 | Jun 1, 2021 | |
| SLDB Solid Biosciences | Initiates: Buy | n/a | $8.79 | - | 1 | May 27, 2021 | |
| CRSP CRISPR Therapeutics AG | Upgrades: Buy | n/a | $54.83 | - | 1 | Apr 21, 2021 | |
| CALT Calliditas Therapeutics AB (publ) | Initiates: Buy | n/a | $18.65 | - | 1 | Jun 30, 2020 | |
| BDTX Black Diamond Therapeutics | Initiates: Buy | n/a | $5.87 | - | 1 | Feb 24, 2020 | |
| AFMD Affimed | Upgrades: Buy | $18 → $40 | $5.49 | +628.60% | 5 | Aug 28, 2018 | |
| NTLA Intellia Therapeutics | Maintains: Buy | n/a | $21.98 | - | 1 | Nov 1, 2017 |
Dianthus Therapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $21.90
Upside: +78.08%
Cue Biopharma
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.42
Upside: +322.54%
Corbus Pharmaceuticals Holdings
Mar 6, 2024
Upgrades: Buy
Price Target: $4 → $46
Current: $35.64
Upside: +29.07%
Metagenomi
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $8.10
Upside: +183.95%
Tempest Therapeutics
Feb 8, 2024
Initiates: Buy
Price Target: $15
Current: $3.44
Upside: +336.05%
BioCryst Pharmaceuticals
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $4.27
Upside: +157.61%
Allakos
May 12, 2023
Upgrades: Buy
Price Target: $6 → $9
Current: $1.10
Upside: +718.18%
Compass Therapeutics
Jan 31, 2023
Initiates: Buy
Price Target: $8
Current: $1.46
Upside: +447.95%
Vera Therapeutics
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $41.38
Upside: -85.50%
Arrowhead Pharmaceuticals
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $23.13
Upside: +224.25%
Alnylam Pharmaceuticals
Oct 3, 2022
Maintains: Buy
Price Target: $218 → $232
Current: $147.36
Upside: +57.44%
Rezolute
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $2.61
Upside: +321.46%
Tyra Biosciences
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $16.45
Upside: +64.13%
BeyondSpring
Dec 2, 2021
Downgrades: Hold
Price Target: n/a
Current: $2.22
Upside: -
Celcuity
Sep 7, 2021
Initiates: Buy
Price Target: n/a
Current: $16.05
Upside: -
ASLAN Pharmaceuticals
Jul 9, 2021
Initiates: Buy
Price Target: n/a
Current: $0.46
Upside: -
Valneva SE
Jun 1, 2021
Initiates: Buy
Price Target: n/a
Current: $7.69
Upside: -
Solid Biosciences
May 27, 2021
Initiates: Buy
Price Target: n/a
Current: $8.79
Upside: -
CRISPR Therapeutics AG
Apr 21, 2021
Upgrades: Buy
Price Target: n/a
Current: $54.83
Upside: -
Calliditas Therapeutics AB (publ)
Jun 30, 2020
Initiates: Buy
Price Target: n/a
Current: $18.65
Upside: -
Black Diamond Therapeutics
Feb 24, 2020
Initiates: Buy
Price Target: n/a
Current: $5.87
Upside: -
Affimed
Aug 28, 2018
Upgrades: Buy
Price Target: $18 → $40
Current: $5.49
Upside: +628.60%
Intellia Therapeutics
Nov 1, 2017
Maintains: Buy
Price Target: n/a
Current: $21.98
Upside: -